Get the Stockscreener App
14.55
5.03%
-0.77
After Hours:
14.52
-0.03
-0.21%
Greenwich Lifesciences Inc stock is traded at $14.55, with a volume of 106.96K.
It is down -5.03% in the last 24 hours and down -6.91% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
See More
Previous Close:
$15.32
Open:
$15.3
24h Volume:
106.96K
Relative Volume:
0.76
Market Cap:
$213.57M
Revenue:
Net Income/Loss:
$-21.76M
P/E Ratio:
-9.3998
EPS:
-1.5479
Net Cash Flow:
$-12.78M
1W Performance:
-11.98%
1M Performance:
-6.91%
6M Performance:
-46.31%
1Y Performance:
+49.69%
1-Day Range:
$14.41
$15.53
1-Week Range:
$14.06
$18.00
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
14.55 | 213.57M | 0 | -21.76M | -12.78M | -1.5479 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily
Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily
HER2-Positive Breast Cancer Pipeline 2026: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - StreetInsider
Understanding Momentum Shifts in (GLSI) - Stock Traders Daily
Greenwich Lifesciences Inc (GLSI-Q) Stock Price and News - The Globe and Mail
Greenwich LifeSciences (GLSI) Short Interest & Short Float | Updated Oct 2026 $GLSI - MarketBeat
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
One Greenwich LifeSciences Insider Raised Their Stake In The Previous Year - simplywall.st
Greenwich LifeSciences (GLSI) Slips 1.40% to $14.74, Holds Above Key SupportStock Picks - dars.gov.et
Understanding the Setup: (GLSI) and Scalable Risk - Stock Traders Daily
Why is Greenwich LifeSciences stock rallying today? - Investing.com
Why is Greenwich LifeSciences stock rallying today? - Investing.com
Greenwich (GLSI) Earnings Check: EPS Misses Its Estimate under the Current Snapshot; Post-Earnings Trading: The Share Price Sheds 0.69% on the DayAnnual Financial Report - vinanet.vn
Greenwich Lifesciences Stock Price Forecast. Should You Buy GLSI? - StockInvest.us
Greenwich Lifesciences Inc (NASDAQ: GLSI) Share Price, GLSI Stock News, GLSI Share Price & Updates - Kalkine
GLSI Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D InvestmentEarnings Revision Downgrade - vinanet.vn
Greenwich Lifesciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results - MarketBeat
Greenwich LifeSciences 2Q 2026: Revenue $0 Net loss $(3.95M), EPS $(0.27) — 10-Q Summary - TradingView
Greenwich LifeSciences | 10-Q: Q2 2026 Earnings Report - Moomoo
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance Singapore
Greenwich LifeSciences (GLSI) posts higher H1 2026 loss and flags going concern risk - Stock Titan
Greenwich Lifesciences Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Responsive Playbooks and the GLSI Inflection - Stock Traders Daily
Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027 - Quiver Quantitative
Greenwich LifeSciences Directors, Officers Face 100% Lock-Up to 2027 - Stock Titan
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 - globenewswire.com
Greenwich LifeSciences (GLSI) Expected to Post Earnings on Thursday - MarketBeat
Understanding the Setup: (GLSI) and Scalable Risk - Stock Traders Daily
Form 4 Greenwich Lifesciences Inc For: 30 July By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock By Investing.com - Investing.com Nigeria
Form 4 Greenwich Lifesciences Inc For: 30 July By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock - Investing.com
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com - Investing.com UK
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com - Investing.com South Africa
Form 4 Greenwich Lifesciences Inc For: 29 July By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares - investing.com
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares - MarketBeat
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com Nigeria
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com Canada
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com UK
Greenwich LifeSciences CEO buys $47,018 in company stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO buys $47,018 in company stock - Investing.com
Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys - Stock Titan
Greenwich LifeSciences CEO buys $47,018 in company stock - investing.com
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jul 29 '26 |
Buy |
13.10 |
700 |
9,170 |
5,611,402 |
| Patel Snehal | CEO and CFO |
Jul 27 '26 |
Buy |
13.62 |
1,500 |
20,430 |
5,609,202 |
| Patel Snehal | CEO and CFO |
Jul 24 '26 |
Buy |
12.88 |
1,100 |
14,168 |
5,607,702 |
| Patel Snehal | CEO and CFO |
Jul 23 '26 |
Buy |
13.14 |
2,500 |
32,850 |
5,606,602 |
| Patel Snehal | CEO and CFO |
Jan 13 '26 |
Buy |
29.83 |
1,800 |
53,694 |
5,604,102 |
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):